Cell cycle arrest triggered by conjugated eicosapentaenoic acid occurs through several mechanisms including G1 checkpoint activation by induced RPA and ATR expression.
BACKGROUND
Conjugated eicosapentaenoic acid (cEPA) containing conjugated double bonds, which is prepared by alkaline treatment of eicosapentaenoic acid (EPA), selectively inhibited the activities of both mammalian DNA polymerases (pols) and human DNA topoisomerases (topos).


METHODS
Human colon carcinoma cell line, HCT116, was cultured and performed drug and small interfering RNA (siRNA) treatment, flow cytometry analysis, BrdU incorporation analysis, and western blot analysis.


RESULTS
The levels of bromodeoxyuridine (BrdU) incorporation labeling during DNA synthesis were decreased in time- and dose-dependent manners in HCT116 cells, treated with cEPA. The level of chromatin association of RPA70, a subunit of the single-stranded DNA (ssDNA)-binding protein, was increased following cEPA exposure, suggesting that the replication forks were stalled in response to inhibition of replicative pol activity by cEPA in the cells. cEPA also induced the activation of ataxia-telangiectasia and Rad3-related (ATR) protein in HCT116 cells, and activated the G1 checkpoint pathway in the cells, which was down-regulated by a small interfering RNA (siRNA) against ATR protein. Moreover, caffeine, a known ATR kinase inhibitor, abrogated the cEPA-induced G1 checkpoint in HCT116 cells.


CONCLUSIONS
cEPA could inhibit the activity of replicative pols, such as pols alpha, delta and epsilon, affect the DNA replication fork including ssDNA, and then activate the G1 checkpoint pathway by the induction of RPA and ATR expression levels in cancer cells.
Kumamoto-Yonezawa
Yuko
Y
Laboratory of Food and Nutritional Sciences, Department of Nutritional Science, Kobe-Gakuin University, Kobe, Hyogo 651-2180, Japan.
Sasaki
Ryohei
R
Ota
Yosuke
Y
Suzuki
Yoko
Y
Fukushima
Shoji
S
Hada
Takahiko
T
Uryu
Keisuke
K
Sugimura
Kazuro
K
Yoshida
Hiromi
H
Mizushina
Yoshiyuki
Y
D064007:Ataxia Telangiectasia Mutated Proteins; D015153:Blotting, Western; D018797:Cell Cycle Proteins / Q000378:metabolism*; D049109:Cell Proliferation / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004249:DNA Damage; D004261:DNA Replication / Q000187:drug effects; D026942:DNA Topoisomerases / Q000378:metabolism; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000737:chemistry* / Q000494:pharmacology*; D016193:G1 Phase / Q000187:drug effects*; D045325:HCT116 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D008954:Models, Biological; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D034622:RNA Interference / Q000187:drug effects; D051716:Replication Protein A / Q000378:metabolism*; D014162:Transfection
D018797:Cell Cycle Proteins; D051716:Replication Protein A; D004247:DNA; D015118:Eicosapentaenoic Acid; C576597:ATR protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases; D004259:DNA-Directed DNA Polymerase; D026942:DNA Topoisomerases